The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Andrew WeiOn May 1, 2020, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) and granted priority review to CC-486, an oral formulation of the hypomethylating agent azacitidine, for maintenance treatment of adult patients with acute myeloid leukemia (AML).
The NDA was based on the results of the phase III QUAZAR AML-001 study on patients with AML in complete remission (CR) or CR with incomplete blood count recovery (CRi) after induction therapy (with or without consolidation), who do not proceed to hematopoietic stem cell transplantation. The study showed a significant improvement in overall survival and relapse-free survival for patients receiving CC-486 maintenance treatment in comparison to patients in the placebo group. No unexpected adverse events were observed. Data from this trial were presented at the 61st American Society of Hematology (ASH) meeting by Andrew Wei, read more here.
The oral formulation of CC-486 allows for extended exposure to the drug, prolonging the therapeutic activity.
QUAZAR: Should maintenance with CC-486 become standard of care following induction chemotherapy?
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content